| |
|
|
|
Enlivex Therapeutics Ltd.  
|
|
5.31 0.05 (0.01%) |
09-18 16:00 |
|
Open: |
5.21 |
Pre close: |
5.26 |
Target:
|
6.40
|
|
High: |
5.31 |
Low: |
5.17 |
Resistance:
|
5.48
6.40
|
|
Volume: |
16,069 |
Market Cap: |
71M |
Support:
|
4.87
4.49
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
5.25
 |
MACD |
MACD(12,26):
|
-0.01 |
|
MA(20): |
5.04 |
Signal(12,26,9): |
-0.07 |
|
MA(100): |
5.36  |
Stochastic Oscillator |
%K(14,3):
|
77.90 |
|
MA(250): |
7.24 |
%D(3): |
74.26 |
|
Average Volume(K) |
3-Month: |
7995
|
52-Week |
High:
|
40.14 |
|
10-Days: |
6071 |
Low: |
3.59 |
|
RSI |
RSI(14):
|
55.00 |
Change(%): |
-86.5 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.819 |
Return on Equity (ttm) |
-39.9 |
Shares Out. (M) |
13.46 |
|
EPS Est. Current Year |
0.000 |
Return on Assets (ttm) |
-20.2 |
Shares Float (M) |
7.35 |
|
EPS Est. Next Year |
0.000 |
PEG Ratio |
0.00 |
% Held by Insiders |
42.08 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
12.59 |
|
Forward EPS |
-1.400 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
49 |
|
Book Value (p.s.) |
2.240 |
EBITDA (p.s.) |
-0.658 |
P/E |
-6.48 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
2.37 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-6.59 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-4.41 |
P/CF |
-10.85 |
|
|
|
|
|
|
